Teruo Hideshima

Q: What Schools Are Affiliated With Teruo Hideshima

Teruo Hideshima is affiliated with the following schools: University of Arkansas for Medical Sciences, Hokkaido University, Vrije Universiteit Amsterdam, University of Leeds, University of Michigan, Tongji University, Fukuoka University, Rush University, Massachusetts General Hospital

Teruo Hideshima's AcademicInfluence.com Rankings

Teruo Hideshima

Philosophy

#5078

World Rank

#7797

Historical Rank

Logic

#2416

World Rank

#3404

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Teruo Hideshima's Degrees

PhD Medical Science University of Tokyo
Doctorate Medicine University of Tokyo

Why Is Teruo Hideshima Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Teruo Hideshima's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

A phase 2 study of bortezomib in relapsed, refractory myeloma. (2003) (2631)
The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. (2001) (1584)
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. (2001) (909)
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. (2000) (902)
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets (2007) (885)
NF-κB as a Therapeutic Target in Multiple Myeloma* (2002) (854)
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. (2010) (813)
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. (2002) (801)
Molecular sequelae of proteasome inhibition in human multiple myeloma cells (2002) (769)
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. (2003) (730)
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. (2002) (670)
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. (2005) (661)
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. (2004) (652)
Advances in biology of multiple myeloma: clinical applications. (2004) (623)
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. (2005) (593)
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. (2003) (589)
Proteasome inhibition as a novel therapeutic target in human cancer. (2005) (570)
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. (2004) (570)
Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications (2001) (544)
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. (2012) (521)
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. (2006) (511)
Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma (2001) (505)
Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. (2002) (493)
Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications (2002) (491)
A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. (2012) (466)
NF-kappa B as a therapeutic target in multiple myeloma. (2002) (464)
Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. (2007) (453)
Molecular mechanisms of novel therapeutic approaches for multiple myeloma (2002) (440)
Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. (2001) (440)
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. (2008) (435)
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. (2005) (431)
TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. (2001) (421)
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. (2009) (419)
The role of tumor necrosis factor α in the pathophysiology of human multiple myeloma: therapeutic applications (2001) (404)
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. (2007) (395)
Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. (2002) (395)
Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. (2006) (349)
Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. (2009) (347)
Antimyeloma activity of heat shock protein-90 inhibition. (2005) (327)
Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. (2013) (322)
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application (2005) (317)
Molecular sequelae of histone deacetylase inhibition in human malignant B cells. (2003) (309)
Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. (2006) (291)
Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. (2004) (279)
Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. (2003) (268)
An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection. (1991) (261)
A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. (2009) (257)
Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. (2008) (248)
Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma (2011) (245)
Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. (2003) (244)
Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma (2015) (242)
Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. (2009) (239)
Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. (2003) (238)
RESCUE OF HIPPO CO-ACTIVATOR YAP1 TRIGGERS DNA DAMAGE-INDUCED APOPTOSIS IN HEMATOLOGICAL CANCERS (2014) (235)
NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. (2003) (226)
Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. (2006) (224)
A novel Bcl-2/Bcl-XL/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma (2007) (219)
JNK-dependent Release of Mitochondrial Protein, Smac, during Apoptosis in Multiple Myeloma (MM) Cells* (2003) (215)
Apaf-1/Cytochrome c-independent and Smac-dependent Induction of Apoptosis in Multiple Myeloma (MM) Cells* (2001) (213)
Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease (2010) (210)
Novel therapies targeting the myeloma cell and its bone marrow microenvironment. (2001) (209)
Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling. (2003) (203)
SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK. (2009) (203)
Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma (2008) (202)
Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. (2009) (202)
Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. (2007) (201)
The proteasome and proteasome inhibitors in multiple myeloma (2017) (192)
SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. (2000) (191)
Cytokines modulate telomerase activity in a human multiple myeloma cell line. (2002) (189)
The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma (2006) (189)
The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo (2009) (189)
Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3. (2008) (187)
Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. (2004) (185)
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. (2014) (180)
Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo (2003) (180)
Nuclear Factor-κB p65 Mediates Tumor Necrosis Factor α-induced Nuclear Translocation of Telomerase Reverse Transcriptase Protein (2003) (180)
Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. (2005) (177)
Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma (2003) (177)
Identification of genes regulated by Dexamethasone in multiple myeloma cells using oligonucleotide arrays (2002) (170)
Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. (2005) (169)
PI3K/p110{delta} is a novel therapeutic target in multiple myeloma. (2010) (168)
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. (2009) (164)
Proteasome inhibitor therapy in multiple myeloma (2005) (163)
Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. (2005) (163)
5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells (2007) (162)
VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis. (2004) (162)
Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis. (2004) (161)
miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/β-catenin/BCL9 pathway. (2014) (159)
Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. (2002) (158)
Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance. (2003) (157)
A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells. (2005) (156)
Dual Inhibition of Akt/Mammalian Target of Rapamycin Pathway by Nanoparticle Albumin-Bound–Rapamycin and Perifosine Induces Antitumor Activity in Multiple Myeloma (2010) (155)
Essential Role of Caveolae in Interleukin-6- and Insulin-like Growth Factor I-triggered Akt-1-mediated Survival of Multiple Myeloma Cells* (2003) (154)
Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). (2004) (153)
Identification of genes modulated in multiple myeloma using genetically identical twin samples. (2004) (151)
Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells. (2005) (145)
The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. (2007) (144)
JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells. (2007) (143)
MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. (2007) (143)
A novel proteasome inhibitor NPI-0052 as an anticancer therapy (2006) (140)
Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells. (2003) (140)
Multiple myeloma: biology of the disease. (2010) (140)
Thalidomide: emerging role in cancer medicine. (2002) (140)
Clinical, Radiographic, and Biochemical Characterization of Multiple Myeloma Patients with Osteonecrosis of the Jaw (2008) (139)
Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. (2004) (138)
Proteasome inhibition in multiple myeloma: therapeutic implication. (2005) (134)
The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. (2004) (131)
Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. (2004) (130)
Neutralizing B-Cell–Activating Factor Antibody Improves Survival and Inhibits Osteoclastogenesis in a Severe Combined Immunodeficient Human Multiple Myeloma Model (2007) (129)
A pivotal role for Mcl-1 in Bortezomib-induced apoptosis (2008) (128)
The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. (2007) (127)
The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma. (2002) (127)
Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes. (2003) (126)
2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells. (2002) (125)
A Novel Role for CCL3 (MIP-1α) in Myeloma-induced Bone Disease via Osteocalcin Downregulation and Inhibition of Osteoblast Function (2011) (125)
Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti‐myeloma activity in vitro and in vivo (2010) (125)
Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. (2004) (123)
Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. (2011) (123)
Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. (2005) (123)
Bortezomib: proteasome inhibition as an effective anticancer therapy. (2006) (122)
Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition. (2012) (122)
Histone deacetylase 3 as a novel therapeutic target in multiple myeloma (2014) (120)
Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. (2003) (119)
Video-assisted thoracoscopic esophagectomy for esophageal cancer (1999) (119)
Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein. (2003) (118)
RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells (1999) (117)
Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl). (2006) (116)
Aurora kinase A is a target of Wnt/beta-catenin involved in multiple myeloma disease progression. (2009) (115)
MLN120B, a Novel IκB Kinase β Inhibitor, Blocks Multiple Myeloma Cell Growth In vitro and In vivo (2006) (114)
CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling. (2003) (113)
20 KDa homologous restriction factor of complement resembles T cell activating protein. (1989) (113)
A High-Affinity Fully Human Anti–IL-6 mAb, 1339, for the Treatment of Multiple Myeloma (2009) (112)
Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells (2007) (112)
Proteasome Inhibition in the Treatment of Cancer (2005) (111)
Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. (2007) (110)
Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications. (2003) (110)
AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition (2010) (108)
FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance. (2005) (108)
p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells (2004) (107)
Transforming Growth Factor β Receptor I Kinase Inhibitor Down-Regulates Cytokine Secretion and Multiple Myeloma Cell Growth in the Bone Marrow Microenvironment (2004) (105)
Gene expression analysis of B‐lymphoma cells resistant and sensitive to bortezomib * (2006) (104)
Novel therapeutic approaches for multiple myeloma (2003) (104)
Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma (2005) (102)
Targeting NF-kappaB in Waldenstrom macroglobulinemia. (2008) (101)
High-Dose Zoledronic Acid Impacts Bone Remodeling with Effects on Osteoblastic Lineage and Bone Mechanical Properties (2009) (99)
Ascorbic acid inhibits antitumor activity of bortezomib in vivo (2009) (98)
Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia. (2007) (96)
Novel therapeutic strategies for multiple myeloma. (2015) (96)
Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma (2016) (93)
Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myeloma. (2009) (93)
Combination Mammalian Target of Rapamycin Inhibitor Rapamycin and HSP90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin Has Synergistic Activity in Multiple Myeloma (2006) (91)
Bortezomib in the front-line treatment of multiple myeloma (2008) (91)
Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. (2008) (90)
The malignant clone and the bone-marrow environment. (2007) (89)
Caveolin-1 Is Required for Vascular Endothelial Growth Factor-Triggered Multiple Myeloma Cell Migration and Is Targeted by Bortezomib (2004) (89)
Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells. (2016) (88)
Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma. (2003) (87)
HDAC Inhibition by LBH589 Affects Phenotype and Function of Human Myeloid Dendritic Cells (2010) (87)
GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment. (2004) (87)
Bortezomib as an antitumor agent. (2006) (85)
Novel therapies for multiple myeloma (2003) (85)
Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma. (2015) (85)
A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells (2015) (84)
Effects of oligonucleotide N3'-->P5' thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells. (2003) (84)
Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity. (2013) (83)
The KDM3A–KLF2–IRF4 axis maintains myeloma cell survival (2015) (83)
Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells. (2004) (81)
Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma (2004) (81)
Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays. (2003) (81)
Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications. (2009) (80)
Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity (2012) (80)
Identification and validation of novel therapeutic targets for multiple myeloma. (2005) (80)
Targeting the Phosphatidylinositol 3-Kinase Pathway in Multiple Myeloma (2007) (78)
Biologic sequelae of c-Jun NH2-terminal kinase (JNK) activation in multiple myeloma cell lines (2003) (78)
Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors (2018) (78)
Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia. (2008) (77)
The emerging role of novel therapies for the treatment of relapsed myeloma. (2007) (77)
Characterization of signaling cascades triggered by human interleukin-6 versus Kaposi's sarcoma-associated herpes virus-encoded viral interleukin 6. (2000) (77)
Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Encouraging Efficacy in High Risk Groups with Updated Results of a Phase I/II Study (2008) (77)
New Proteasome Inhibitors in Myeloma (2012) (76)
Interactions of the Hdm2/p53 and Proteasome Pathways May Enhance the Antitumor Activity of Bortezomib (2009) (76)
The use of novel agents in the treatment of relapsed and refractory multiple myeloma (2009) (75)
MUC1-C drives MYC in multiple myeloma. (2016) (74)
Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma. (2000) (74)
TNFalpha induces rapid activation and nuclear translocation of telomerase in human lymphocytes. (2004) (74)
Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma. (2003) (73)
Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma (2011) (71)
CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines. (2000) (71)
Emerging Therapies for Multiple Myeloma (2006) (71)
Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma (2012) (70)
Proteasome inhibition (2004) (70)
Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling. (2008) (68)
Critical Role for Hematopoietic Cell Kinase (Hck)-mediated Phosphorylation of Gab1 and Gab2 Docking Proteins in Interleukin 6-induced Proliferation and Survival of Multiple Myeloma Cells* (2004) (68)
CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells. (2008) (68)
Proteasome inhibition in hematologic malignancies (2004) (68)
Inhibition of p38α MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-XL, Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo (2006) (66)
The number of lymph node metastases influences survival in esophageal cancer (1998) (66)
MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. (2006) (65)
Lenalidomide Plus Bortezomib (Rev-Vel) in Relapsed and/or Refractory Multiple Myeloma (MM): Final Results of a Multicenter Phase 1 Trial. (2006) (65)
In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma. (2013) (65)
KDM6B modulates MAPK pathway mediating multiple myeloma cell growth and survival (2017) (65)
Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. (2009) (64)
Detection of Kaposi's sarcoma herpesvirus DNA sequences in multiple myeloma bone marrow stromal cells. (1999) (64)
Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition. (2014) (64)
Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma (2009) (64)
Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway (2005) (63)
Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo (2009) (62)
Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cells (2003) (61)
Phase transitions in human IgG solutions. (2013) (59)
Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study (2012) (58)
SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. (2005) (58)
Intracellular Protein Degradation and Its Therapeutic Implications (2005) (58)
p38 mitogen‐activated protein kinase inhibitor LY2228820 enhances bortezomib‐induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications (2008) (57)
Ku86 Variant Expression and Function in Multiple Myeloma Cells Is Associated with Increased Sensitivity to DNA Damage1 (2000) (57)
Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma (2015) (57)
Antimyeloma Activity of a Multitargeted Kinase Inhibitor, AT9283, via Potent Aurora Kinase and STAT3 Inhibition Either Alone or in Combination with Lenalidomide (2011) (57)
Targeting Akt and Heat Shock Protein 90 Produces Synergistic Multiple Myeloma Cell Cytotoxicity in the Bone Marrow Microenvironment (2008) (56)
HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications (2017) (56)
Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341 (2004) (56)
Histone deacetylase inhibitors in multiple myeloma: from bench to bedside (2016) (55)
Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma. (2007) (55)
Functional activity of an HIV-1 neutralizing IgG human monoclonal antibody: ADCC and complement-mediated lysis. (1992) (55)
Discrimination of double primary lung cancer from intrapulmonary metastasis by p53 gene mutation (1999) (54)
Novel biological therapies for the treatment of multiple myeloma. (2005) (54)
Molecular Motion in Solid State Polymers (1963) (53)
Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo. (2005) (53)
Recombinant humanized anti‐CD40 monoclonal antibody triggers autologous antibody‐dependent cell‐mediated cytotoxicity against multiple myeloma cells (2003) (53)
BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen‐activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth (2007) (52)
Cytokines and signal transduction. (2005) (51)
Targeting proteasomes as therapy in multiple myeloma. (2008) (51)
Significant Biological Role of Sp1 Transactivation in Multiple Myeloma (2011) (50)
A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity (2018) (50)
Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma (2015) (50)
Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma (2018) (50)
Isolation and characterization of human multiple myeloma cell enriched populations. (2000) (49)
Small Molecule Multi-Targeted Kinase Inhibitor RGB-286638 Triggers P53-Dependent and -Independent Anti-Multiple Myeloma Activity through Inhibition of Transcriptional CDKs (2013) (48)
A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells. (2010) (48)
Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-β inhibitors (2005) (48)
Proteasome inhibition as a new therapeutic principle in hematological malignancies. (2006) (47)
The Cyclophilin A–CD147 complex promotes the proliferation and homing of multiple myeloma cells (2015) (47)
Lenalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Encouraging Response Rates and Tolerability with Correlation of Outcome and Adverse Cytogenetics in a Phase II Study. (2008) (47)
A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications (2016) (46)
Protein Arginine Methyltransferase 5 (PRMT5) has prognostic relevance and is a druggable target in Multiple Myeloma (2017) (46)
Liposomal carfilzomib nanoparticles effectively target multiple myeloma cells and demonstrate enhanced efficacy in vivo. (2014) (46)
Novel therapies in the treatment of multiple myeloma. (2009) (45)
Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma (2007) (43)
Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling (2019) (42)
Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo. (2006) (41)
JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications. (2020) (41)
New insights into the treatment of multiple myeloma with histone deacetylase inhibitors. (2012) (41)
Multi-Center Phase II Study of Perifosine (KRX-0401) Alone and in Combination with Dexamethasone (dex) for Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Promising Activity as Combination Therapy with Manageable Toxicity. (2007) (39)
The treatment of relapsed and refractory multiple myeloma. (2007) (39)
A Phase 1 Trial of Lenalidomide (REVLIMID®) with Bortezomib (VELCADE®) in Relapsed and Refractory Multiple Myeloma. (2005) (38)
A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma (2008) (38)
Current therapeutic uses of lenalidomide in multiple myeloma (2006) (37)
Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. (2004) (37)
Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of b1-integrin and phosphatidylinositol 3-kinase/AKT signaling beta. (2003) (36)
Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide (2014) (35)
Targeting proteasome inhibition in hematologic malignancies. (2003) (35)
Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs (2005) (35)
Functional significance of novel neurotrophin‐1/B cell‐stimulating factor‐3 (cardiotrophin‐like cytokine) for human myeloma cell growth and survival (2003) (35)
Lenalidomide in multiple myeloma (2006) (35)
Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) as Front-Line Therapy for Patients with Multiple Myeloma (MM): Preliminary Results of a Phase 1/2 Study. (2007) (34)
β-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells (2002) (33)
2-Methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating Heat Shock Protein-27 (2004) (32)
Targeting signalling pathways for the treatment of multiple myeloma (2005) (32)
A phase 1 study of oral CC5013, an immunomodulatory thalidomide (Thal) derivative, in patients with relapsed and refractory multiple myeloma (MM). (2001) (32)
Phase I/II Results of a Multicenter Trial of Perifosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Who Were Previously Relapsed from or Refractory to Bortezomib (2008) (32)
Proteasomal Degradation of Topoisomerase I Is Preceded by c-Jun NH2-Terminal Kinase Activation, Fas Up-Regulation, and Poly(ADP-Ribose) Polymerase Cleavage in SN38-Mediated Cytotoxicity against Multiple Myeloma (2004) (32)
p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma. (2017) (32)
Absence of biologically important Kaposi sarcoma-associated herpesvirus gene products and virus-specific cellular immune responses in multiple myeloma. (2002) (32)
Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathways (2020) (31)
Pathological crystallization of human immunoglobulins (2012) (31)
Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Results of a Phase II Study. (2007) (31)
Retraction: Fatty acid synthase is a novel therapeutic target in multiple myeloma (2008) (31)
Lenalidomide for the treatment of relapsed and refractory multiple myeloma (2012) (31)
Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents (2012) (30)
Phase II Trial of Lenalidomide, Bortezomib, and Dexamethasone In Patients (pts) with Relapsed and Relapsed/Refractory Multiple Myeloma (MM): Updated Efficacy and Safety Data After >2 Years of Follow-up (2010) (30)
Medroxyprogesterone acetate treatment reduces serum interleukin‐6 levels in patients with metastatic breast carcinoma (1996) (30)
Expression of HRF20, a regulatory molecule of complement activation, on peripheral blood mononuclear cells. (1990) (30)
P38 MAPK Inhibition Enhances PS-341 (bortezomib)-Induced Cytotoxicity Against Multiple Myeloma Cells. (2004) (29)
Histone deacetylase inhibitors in the treatment for multiple myeloma (2013) (29)
In vitro anti‐myeloma activity of the Aurora kinase inhibitor VE‐465 (2009) (29)
The power of proteasome inhibition in multiple myeloma (2018) (28)
Apoptotic Signaling in Multiple Myeloma: Therapeutic Implications (2003) (28)
The biological significance of histone modifiers in multiple myeloma: clinical applications (2018) (28)
Biologic impact of proteasome inhibition in multiple myeloma cells--from the aspects of preclinical studies. (2012) (28)
Proteasome inhibitors as therapeutics. (2005) (28)
p53 mutations predict non-small cell lung carcinoma response to radiotherapy. (1999) (27)
Functional interaction between retinoblastoma protein and stress-activated protein kinase in multiple myeloma cells. (1999) (27)
New treatments for multiple myeloma. (2005) (27)
Relaxation Spectroscopy of the Dielectric β-Relaxation in Poly(n-alkyl methacrylate)s by Absorption–Current Measurements. I. Dielectric Relaxation Spectra for Atactic Polymers (1982) (27)
Thalidomide in multiple myeloma. (2002) (27)
Phase I Results of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (MM) (2008) (26)
PI3K/p110 is a novel therapeutic target in multiple myeloma (2011) (26)
Novel therapies in MM: from the aspect of preclinical studies (2011) (26)
β-catenin is dynamically stored and cleared in multiple myeloma by the proteasome–aggresome–autophagosome–lysosome pathway (2012) (26)
Expression of steroid receptors, Ki-67, and epidermal growth factor receptor in tamoxifen-treated endometrium. (1999) (26)
Novel etodolac analog SDX-308 (CEP-18082) induces cytotoxicity in multiple myeloma cells associated with inhibition of β-catenin/TCF pathway (2007) (26)
Delineating the mTOR Kinase Pathway Using a Dual TORC1/2 Inhibitor, AZD8055, in Multiple Myeloma (2014) (25)
Biological pathways and in vivo antitumor activity induced by Atiprimod in myeloma (2007) (25)
Telomerase inhibitors as anticancer therapy. (2002) (24)
Signaling Pathway Mediating Myeloma Cell Growth and Survival (2021) (24)
Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation. (2020) (23)
MUC1‐C is a target in lenalidomide resistant multiple myeloma (2017) (23)
Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings (2011) (22)
The Cyclophilin A-CD147 complex promotes bone marrow colonization of B-cell malignancies: implications for therapy (2015) (22)
Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status (2016) (22)
Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma (2006) (22)
Niche-Based Screening in Multiple Myeloma Identifies a Kinesin-5 Inhibitor with Improved Selectivity over Hematopoietic Progenitors. (2015) (22)
Preclinical studies of novel targeted therapies. (2007) (22)
Heteroclitic XBP1 peptides evoke tumor-specific memory cytotoxic T lymphocytes against breast cancer, colon cancer, and pancreatic cancer cells (2014) (21)
Plasma Cell Tumors (2003) (21)
Proteasome inhibitor PS-341 inhibits human multiple myeloma cell growth in a murine model. (2001) (21)
Didox, a ribonucleotide reductase inhibitor, induces apoptosis and inhibits DNA repair in multiple myeloma cells (2006) (21)
Low Frequency Coupled Oscillator and its Application to High Polymer Study (1953) (21)
A mouse/human-chimeric bispecific antibody reactive with human carcinoembryonic antigen-expressing cells and human T-lymphocytes. (1996) (20)
Benign epithelial cyst of the spleen with a high production of carbohydrate antigen 19-9. (1999) (20)
Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma (2017) (20)
Targeting NF-B in Waldenstrom macroglobulinemia (2008) (20)
Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma (2017) (19)
Creep of Polymethyl Methacrylate at Low Temperature (1954) (19)
Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy (2009) (19)
Multiple relaxation in a- and ?-loss bands of polyethylene (1973) (19)
HDAC Inhibition by LBH 589 Affects Phenotype and Function of Human Myeloid Dendritic Cells (2013) (19)
Alkyl phospholipid perifosine induces myeloid hyperplasia in a murine myeloma model. (2007) (18)
Identification and characterization of HLA-A24-specific XBP1, CD138 (Syndecan-1) and CS1 (SLAMF7) peptides inducing antigens-specific memory cytotoxic T lymphocytes targeting multiple myeloma (2018) (18)
in patients with multiple myeloma Elevated soluble MUC 1 levels and decreased anti-MUC 1 antibody levels (2000) (18)
TRIM13 (RFP2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activity (2013) (18)
Dynamical Study on the Secondary Anomalous Absorption Region of Polymethyl Methacrylate (1953) (18)
Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells (2015) (18)
Detection of chromogranin A mRNA in small cell lung carcinoma using a new, highly sensitive in Situ hybridization method with a non‐radioisotope oligonucleotide probe (1998) (18)
AT7519, a Novel Small Molecule Multi-Cyclin Dependent Kinase Inhibitor, Induces Apoptosis in Multiple Myeloma VIA GSK3β (2008) (18)
Novel therapeutic avenues in myeloma: changing the treatment paradigm. (2007) (17)
Glutathione S-transferase mu1 null genotype is associated with K-ras gene mutation in lung adenocarcinoma among smokers. (2001) (17)
Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma (2021) (17)
Phase I/II Report from a Multicenter Trial of Perifosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Previously Treated with Bortezomib. (2007) (17)
IKKβ inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells (2014) (16)
Proteasome inhibition as a therapeutic strategy for hematologic malignancies (2005) (16)
In vivo and in vitro cytotoxicity of R‐etodolac with dexamethasone in glucocorticoid‐resistant multiple myeloma cells (2006) (16)
Induction of differential apoptotic pathways in multiple myeloma cells by class-selective histone deacetylase inhibitors (2014) (15)
Bortezomib Induces Anti-Multiple Myeloma Immune Response Mediated by cGAS/STING Pathway Activation. (2021) (15)
Comparative study of dielectric, mechanical, and nuclear magnetic relaxations in linear polyethylene. II. Relaxation spectroscopy of the α, β, and γ loss bands with special emphasis on fine structure (1985) (14)
Perifosine in Combination with Bortezomib and Dexamethasone Extends Progression-Free Survival and Overall Survival in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezombib: Updated Phase I/II Trial Results. (2009) (14)
Comparative study of dielectric, mechanical, and nuclear magnetic relaxations of linear polyethylene. I. Broad‐line NMR investigation of the fine structure of the α and γ loss bands observed by dielectric and mechanical measurements (1985) (14)
A Multicenter Phase II Study of Perifosine (KRX-0401) Alone and in Combination with Dexamethasone (Dex) for Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM). (2006) (14)
Novel targeted agents in the treatment of multiple myeloma. (2014) (14)
Postoperative chylothorax following partial resection of mediastinal lymphangioma: Report of a case (1995) (14)
selective HDAC 6 inhibitor , ACY-1215 , in combination with bortezomib in Preclinical activity , pharmacodynamic and pharmacokinetic properties of a (2012) (13)
RGB 286638, a Novel Multi-Targeted Small Molecule Inhibitor, Induces Multiple Myeloma (MM) Cell Death through Abrogation of CDKDependent and Independent Survival Mechanisms (2008) (13)
Erratum: Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma (Leukemia (2008) vol. 22 (1925-1932) 10.1038/leu.2008.174) (2008) (13)
A Multiple Myeloma Research Consortium (MMRC) Multicenter Phase I Trial of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (MM): Updated Results. (2007) (12)
Recent advances in the treatment of Multiple Myeloma. (2006) (12)
An update of novel therapeutic approaches for multiple myeloma (2004) (11)
HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer. (2017) (11)
High Response Rates and Encouraging Time-to-Event Data with Lenalidomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Final Results of a Phase I/II Study. (2009) (11)
Emerging drugs in multiple myeloma (2007) (11)
The potential benefits of participating in early‐phase clinical trials in multiple myeloma: long‐term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib (2012) (11)
Relaxation Spectroscopy of the Dielectric β-Relaxation in Poly(n-alkyl methacrylate)s by Absorption-Current Measurements. II. Dielectric Relaxation Spectrum for Isotactic Poly(methyl methacrylate) (1982) (10)
PI 3 K / p 110 is a novel therapeutic target in multiple myeloma (2010) (10)
Effect of the Distribution of Free Volume on the β Relaxation in Poly (Vinylidene Fluoride) (1985) (10)
The mTOR Inhibitor RAD001 (everolimus) Is Active Against Multiple Myeloma Cells In Vitro and in Vivo. (2004) (10)
Novel biologically based therapies for multiple myeloma (2002) (10)
HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer (2017) (10)
Combination of the mTOR inhibitor Rapamycin and Revlimid ( CC-5013 ) has synergistic activity in Multiple Myeloma (2004) (10)
Novel biologically based therapeutic strategies in myeloma. (2002) (10)
Dasatinib (BMS-354825): A Multi-Targeted Kinase Inhibitor with Activity Against Multiple Myeloma. (2005) (10)
Clinical translation in multiple myeloma: from bench to bedside. (2013) (10)
CD 40 induces human multiple myeloma cell migration via phosphatidylinositol 3 – kinase / AKT / NF-B signaling (2003) (10)
Bortezomib in the management of multiple myeloma (2009) (9)
IPI-504: A Novel hsp90 Inhibitor with In Vitro and In Vivo Anti-Tumor Activity. (2004) (9)
Panobinostat Inhibits JAK2/STAT3 Pathway in Multiple Myeloma. (2009) (9)
Selective Inhibition of HDAC6 with a New Prototype Inhibitor (ACY-1215) Overcomes Bortezomib Resistance In Multiple Myeloma (MM) (2010) (9)
Proteasome inhibitors as therapeutics: Figure 1 (2005) (9)
Elevated soluble MUC 1 levels and decreased anti-MUC 1 antibody levels in patients with multiple myeloma (2000) (9)
Insulin-like Growth Factor-1 Induces Adhesion and Migration in Human Multiple Myeloma Cells via Activation of 1-Integrin and Phosphatidylinositol 3-Kinase / AKT Signaling 1 (2003) (9)
Restoration of Bone Balance Via Activin a Inhibition Results in Anti-Myeloma Activity (2008) (9)
Lysine Demethylase 5A Is Required for MYC-Driven Transcription in Multiple Myeloma. (2021) (8)
Deubiquitylating Enzyme USP-7, a Novel Therapeutic Target in Multiple Myeloma. (2009) (8)
Lenalidomide and Bortezomib Inhibit Osteoclast Differentiation and Activation in Multiple Myeloma: Clinical Implications. (2006) (8)
Final Phase I Results of Perifosine In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed or Refractory Multiple Myeloma (MM) (2010) (8)
LAQ824 is a novel histone deacetylase inhibitor with significant activity against multiple myeloma: Results of a pre-clinical evaluation in vitro and in vivo. (2002) (8)
Resistance to Proteasome Inhibitors in Multiple Myeloma (2014) (8)
Anti-Tumor Activity of KOS-953, a Cremophor-Based Formulation of the hsp90 Inhibitor 17-AAG. (2004) (7)
Nifuroxazide Inhibits STAT3 Function and Shows Potent Anti-Tumor Activity Against Multiple Myeloma. (2006) (7)
Combination of a Novel Proteasome Inhibitor NPI-0052 and Lenalidomide Trigger in Vivo Synergistic Cytotoxicity in Multiple Myeloma (2008) (7)
Emerging trends in the clinical use of bortezomib in multiple myeloma. (2005) (7)
Nature of the Anomalous Shape Change in Loss Permittivity versus Frequency Curve of Polymers above and near the Glass Transition Temperature (1990) (7)
ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment (2021) (7)
Kaposi's sarcoma-associated herpesvirus gene sequences are detectable at low copy number in primary amyloidosis (2000) (7)
CD 40 activation mediates p 53-dependent cell cycle regulation in human multiple myeloma cell lines (2000) (7)
HRF20, a membrane inhibitor of complement attack, does not protect cells from the cytotoxic reaction by lymphokine activated killer cells. (1990) (7)
Novel Agent Perifosine Enhances Antitumor Activity of Bortezomib, Rituximab and Other Conventional Therapies in Waldenstrom’s Macroglobulinemia. (2006) (6)
Bortezomib Induces Proliferation of Mesenchymal Progenitor Cells and Promotes Differentiation towards Osteoblastic Lineage. (2006) (6)
TGF-β Receptor I Kinase Inhibitor Downregulates Cytokine Secretion and Multiple Myeloma Cell Growth in the Bone Marrow Microenvironment. (2004) (6)
Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma (2008) (6)
Randomized, placebo‐controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib (2020) (6)
The Apparent Second-Order Transition of High Polymers with Special Emphasis on its Manifestation in the Mechanical Properties (1959) (6)
Targeting Bcl-2 as Therapy for Multiple Myeloma. (2005) (6)
The expression of MDM2 and p53 protein breast carcinoma. (1997) (6)
beta-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells. (2002) (6)
Effect of Distribution of Free Volume on Concentration Dependence of Dielectric Relaxation in Water Mixtures with Poly(Ethylene Glycol) and Glucose (1998) (5)
The Combination of the mTOR Inhibitor Rapamycin and Proteasome Inhibitor Bortezomib Is Synergistic In Vitro in Multiple Myeloma. (2006) (5)
Immunohistochemical analysis of bcl-2 and p53 protein in breast carcinoma. (1996) (5)
Pharmacodynamic and Pharmacokinetic Properties of a Novel and Selective HDAC6 Inhibitor, ACY-1215, in Combination with Bortezomib in Multiple Myeloma (2011) (5)
A Novel Orally Available Proteasome Inhibitor NPI-0052 Induces Killing in Multiple Myeloma (MM) Cells Resistant to Conventional and Bortezomib Therapies. (2004) (5)
Dielectric Relaxations in Poly(γ-n-alkyl L-glutamate) II. Study of Relaxation due to Motion of the Side Chain and that due to Motion of the Main Chain (1986) (5)
Dielectric Relaxations in Poly(γ-n-alkyl L-glutamate)s I. Study of the Relaxations above Room Temperature Using the Direct-Current Technique (1985) (5)
Stress Relaxation Study of Fine Structure of γ-Loss Band of Branched Polyethylene (1982) (5)
Promoting Osteoblastogenesis Using a Novel Dkk-1 Neutralizing Antibody in the Treatment of Multiple Myeloma Related Bone Disease (2008) (5)
Relaxation spectroscopy of poly(vinylidene fluoride) (1984) (5)
A proto-oncogene BCL 6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells (2010) (5)
Multiple Myeloma - a New Era of Treatment Strategies (2012) (5)
Stress Relaxation Study of γ-Loss Band Linear Polyethylene (1977) (5)
Targeting NAD+ Salvage Pathway Induces Autophagy in Multiple Myeloma Cells (2011) (5)
BT062, a CD138-Specific Immunoconjugate, Demonstrates Superior In Vivo Anti-Myeloma Efficacy In Combination with Lenalidomide or Bortezomib (2010) (5)
Biomarker Correlation with Outcomes in Patients with Relapsed or Refractory Multiple Myeloma on a Phase I Study of Everolimus in Combination with Lenalidomide (2011) (4)
A Novel Aurora-a Kinase Inhibitor MLN8237 Induces Cytotoxicity and Cell Cycle Arrest in Experimental Multiple Myeloma Models. (2008) (4)
AZD6244 (ARRY-142886), a Potent and Selective MEK1/2 Inhibitor Blocks the ERK1/2 Signaling Pathway, Inhibits Osteoclast Differentiation and Activation in Multiple Myeloma: Clinical Implications. (2006) (4)
Identification of a Novel Long Intergenic Noncoding RNA - Linc00936, with Significant Impact on Multiple Myeloma Cell Growth Via mTOR Pathway Inhibition (2015) (4)
The CXCR4/SDF-1 Axis Regulates Migration and Adhesion in Waldenstrom Macroglobulinemia. (2006) (4)
The Treatment of Multiple Myeloma Patients Not Eligible for Asct (2010) (4)
Primary tumor levels of interleukin-6 in relation to tumor burden in human breast-cancer. (1994) (4)
The Proteasome Inhibitor NPI-0052 in Combination with Bortezomib Induces Antitumor Activity in Waldenstrom Macroglobulinemia. (2006) (4)
Distribution of Free Volume and Dielectric Relaxation due to Segmental Motion of Amorphous Chains in Chlorinated Poly(ethylene) (1986) (4)
The PKC- Inhibitor Enzastaurin Inhibits MM Cell Growth, Survival and Migration in the Bone Marrow Microenvironment. (2005) (4)
Role of Selective HDAC6 Inhibition On Multiple Myeloma Bone Disease (2012) (4)
The Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor PTK 787 / ZK 222584 Inhibits Growth and Migration of Multiple Myeloma Cells in the Bone Marrow Microenvironment 1 (1998) (4)
The monoclonal antibody nBT062 conjugated to maytansinoids has potent and selective cytotoxicity against CD138 positive multiple myeloma cells in vitro and in vivo (2008) (4)
Combination of Nab-Rapamycin and Perifosine Induces Synergistic Cytotoxicity and Antitumor Activity Via Autophagy and Apoptosis in Multiple Myeloma (MM) (2008) (4)
Immunomodulatory Effects of HDACi in Combination with Checkpoint Blockade and Lenalidomide in the Immunosuppressive Multiple Myeloma Bone Marrow Microenvironment (2017) (4)
Distinct Dynamic Profiles for NPI-0052-And Bortezomib-Induced Apoptosis in Multiple Myeloma. (2006) (4)
Mechanical Relaxation of Poly (Vinylidene Fluoride) and Copolymer of Vinylidene Fluoride and Tetrafluoroethylene in α and β Relaxation Regions (1985) (4)
Novel therapies for multiple myeloma. (2002) (4)
2-methoxyestradiol (2ME2) acts directly on tumor cells and in the bone marrow microenvironment to overcome drug resistance in multiple myeloma (MM) cells. (2001) (4)
A347 Phase I Trial of Perifosine, Lenalidomide, and Dexamethasone in Relapsed or Refractory Myeloma (2009) (4)
antitumor activity in multiple myeloma Small-molecule inhibition of proteasome and aggresome function induces synergistic (2005) (3)
Viscoelastic Behavior and Glass Transition of High Polymers (1961) (3)
Relaxation Spectroscopy of the Mechanical β-Relaxation in Poly(n-alkyl methacrylate)s in Glassy State by Stress Relaxation Measurements (1986) (3)
Combination of a Novel HDAC 6 Inhibitor ACY-241 with Anti-PD-L1 Antibody Enhances Anti-Tumor Immunity and Cytotoxicity in Multiple Myeloma (2016) (3)
The Antidiabetic Biguanide Metformin Induces Growth Arrest in Multiple Myeloma Cells in Vitro, overcoming the Effect of Stromal Cells (2008) (3)
In vitro and in vivo activity of the VEGF receptor inhibitor PAZOPANIB (GW786034) in Multiple Myeloma: Therapeutic implications. (2006) (3)
CAL-101, a Specific Inhibitor of the p110δ Isoform of Phosphatidylinositide 3-Kinase Induces Cytotoxicity in Multiple Myeloma (MM) (2008) (3)
Inhibition of ERK1/2 Activity by the MEK1/2 Inhibitor AZD6244 (ARRY-142886) Induces Human Multiple Myeloma Cell Apoptosis in the Bone Marrow Microenvironment: A New Therapeutic Strategy for MM. (2006) (3)
Preclinical evaluation of a novel and orally active proteasome inhibitor as a therapy in relapsed/refractory multiple myeloma (2005) (3)
Disruption of DEPTOR/mTORC1/mTORC2 Signaling Cascade Using a Novel Selective mTOR Kinase Inhibitor AZD8055 Results In Growth Arrest and Apoptosis In Multiple Myeloma Cells (2010) (3)
PR-924, a Selective Inhibitor of the Immunoproteasome Subunit LMP-7 Blocks Multiple Myeloma Cell Growth Both in Vitro and In Vivo. (2009) (3)
Therapeutics , Targets , and Chemical Biology miR-30-5 p Functions as a Tumor Suppressor and Novel Therapeutic Tool by Targeting the Oncogenic Wnt / b-Catenin / BCL 9 Pathway (2014) (3)
The Selective Protein Kinase CB Inhibitor, Enzastaurin, Induces In Vitro and In Vivo Antitumor Activity in Waldenstrom’s Macroglobulinemia. (2006) (3)
Potentiation of cytotoxicity against a CEA positive cell line by the bispecific antibody OH1 using LAK cells from cancer-bearing patients. (1998) (3)
TAS-117, a Novel Selective Akt Inhibitor Demonstrates Significant Growth Inhibition in Multiple Myeloma Cells in Vitro and in Vivo (2012) (3)
Selective HDAC6 Inhibition Via ACY-1215, Either Alone or in Combination with Bortezomib, Restores Osteoblast Function and Suppresses Osteoclast Differentiation in Multiple Myeloma (2011) (3)
FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma (2006) (3)
Cancer Therapy : Preclinical The Monoclonal Antibody nBT 062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD 138-Positive Multiple Myeloma Cells In vitro and In vivo (2009) (3)
Potential Therapeutic Role of the Selective Adhesion Molecule (SAM) Inhibitor Natalizumab in Multiple Myeloma. (2009) (3)
HDAC 6 inhibitor WT 161 downregulates growth factor receptors in breast cancer (2017) (3)
Targeting IRE1α-XBP1 Pathway Is a Novel Therapeutic Strategy In Multiple Myeloma (2010) (3)
Receptor activator of nuclear factor-kappa B (RANK) ligand expression: In human multiple myeloma cells. (2001) (3)
B203 A New Anti-Dkk-1 Antibody Targeting Myeloma Bone Disease (2009) (2)
Heat shock protein-27 confers drug-resistance in multiple myeloma cells. (2002) (2)
ESR Study of Gel-Sol Transitions of Poly(L-leucine)-Benzene Solution by Spin-Labeling Technique (1987) (2)
Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Final Results of a Phase I/II Trial (2011) (2)
JS-K, a GST-Activated Nitric Oxide Generator, Induces DNA-Double Strand Breaks and Inhibits Growth and Survival of Multiple Myeloma Cells In Vitro and In Vivo. (2006) (2)
Effect of Nitric Acid-Treatment on γ-Loss Band in Linear Polyethylene (1977) (2)
Bortezomib induces canonical nuclear factor- (cid:1) B activation in multiple myeloma cells (2009) (2)
Gabarap Loss Mediates Immune Escape in High Risk Multiple Myeloma (2021) (2)
Anti-Myeloma Activity of the Small-Molecule Aurora Kinase Inhibitor VE465. (2006) (2)
A224 Lenalidomide, Bortezomib, and Dexamethasone Has Notable Activity in High-Risk First-Line Myeloma (2009) (2)
Inhibition of TGF-β Signaling in Multiple Myeloma and Its Bone Marrow Microenvironment (2008) (2)
AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor Induces Antimyeloma Activity Via Potent Aurora Kinase and STAT3 Inhibition. (2009) (2)
Lenalidomide and Bortezomib: Targeting Osteoclastogenesis, Osteoclast Survival Factors, and Bone Remodeling Markers in Multiple Myeloma. (2007) (2)
Pleiotropic activity of the novel cyclin-dependent kinase inhibitor RGB 286638 predicts therapeutic potential in multiple myeloma (2008) (2)
Perifosine, an Oral Bioactive Novel Akt Inhibitor, Induces In Vitro and In Vivo Antitumor Activity in Waldenstrom Macroglobulinemia. (2006) (2)
Dual BCL-2/BCL-XL Inhibitor Pelcitoclax (APG-1252) Overcomes Intrinsic and Acquired Resistance to Venetoclax in Multiple Myeloma Cells (2021) (2)
Distribution of Free Volume and Dielectric α-Relaxation in Glass-Forming Liquid Mixtures (1995) (2)
Critical role for Hck-mediated phosphorylation of Gab1 and Gab2 docking proteins in interleukin-6-induced proliferation and survival of multiple myeloma cells. (2003) (2)
A MIR17HG-derived Long Noncoding RNA Provides an Essential Chromatin Scaffold for Protein Interaction and Myeloma Growth. (2022) (2)
Cells : Clinical Implications Antibody , Induces Cytotoxicity in Human Multiple Myeloma Mechanisms by which SGN-40 , a Humanized Anti-CD 40 (2004) (2)
A new improved technique for placement of a pursestring suture on the edge of the distal part of the rectal stump using a skin stapler for low anterior resection. (1994) (2)
MLN-8237 (2010) (2)
Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma (2000) (2)
Lenalidomide and bortezomib induce osteoclast cytotoxicity and decrease BAFF secretion in osteoclasts in human multiple myeloma: Clinical implications. (2006) (2)
Targeting NF-kB by Perifosine, Bortezomib and Rituximab in Waldenstrom Macroglobulinemia (WM). (2007) (2)
Effects of the indazolylpyrimidine GW786034 on angiogenesis and MM cell growth: Therapeutic implications. (2004) (2)
The Combination of Bortezomib and NPI-0052 Exerts Anti-Tumor Activity in Waldenstrom Macroglobulinemia (WM). (2007) (2)
AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor with Potent Activity Against Aurora Kinase and STAT3 In Combination with Lenalidomide Results In Synergistic Anti-Myeloma Activity (2010) (2)
HDAC Inhibition by LBH589 Affects Phenotype and Function of Human Dendritic Cells. (2009) (2)
TH17 Pathway and Associated Pro-Inflammatory Cytokines Promote Immune Dysfunction in Myeloma. (2007) (2)
Gadolinium Containing Contrast Agent Promotes Multiple Myeloma Cell Growth: Implication for Clinical Use of MRI in Myeloma. (2009) (2)
Novel hydroxamic acid-derived HDAC inhibitor LBH589 potently activates intrinsic and extrinsic apoptotic pathways, and induces tubulin hyperacetylation in multiple myeloma. (2005) (2)
Emerging treatments of multiple myeloma; beyond IMIDs and bortezomib (2009) (2)
Antimyeloma Efficacy of Plitidepsin (Aplidin®): From Bench to the Bedside. (2007) (2)
Dielectric Relaxation Spectroscopy of Chitin and Related Substances (1992) (2)
Targeting MEK1/2 Signaling Cascade by AS703026, a Novel Selective MEK1/2 Inhibitor, Induces Pleiotropic Anti-Myeloma Activity in Vitro and In Vivo. (2009) (2)
B483 A Novel Small-Molecule Inhibitor RGB 286638 Induces Apoptosis and Necrosis in Multiple Myeloma (2009) (2)
The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Potent and Selective Cytotoxicity against CD138 Positive Multiple Myeloma Cells in Vitro and in Vivo. (2008) (2)
PKC412 Is a Multi-Targeting Kinase Inhibitor with Activity Against Multiple Myeloma In Vitro and In Vivo. (2005) (2)
Genome-Wide CRISPR-Cas9 Screening Reveals a Role for TRAF2 in Resistance to IMiDs in Multiple Myeloma (2018) (2)
The Critical Role of HDAC1-IRF4-Pim-2 Axis in Myeloma Cell Growth and Survival: Therapeutic Impacts of Targeting the HDAC1-IRF4-Pim-2 Axis (2018) (2)
Function and expression of checkpoint inhibitors and immune agonists on immune cells in monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM) and MM and tumor-specific T lymphocytes. (2017) (2)
Mitochondria and caspase-independent cell-death triggered by GCS-100, a novel carbohydrate-based therapeutic in multiple myeloma (MM) cells. (2004) (2)
Blocking HDAC3 in Bone Marrow Stromal Cells Has Direct Anti-Multiple Myeloma Effect and Modulates T Cell Function (2017) (2)
The PI3K/Akt Pathway Is an Important Regulator of Homing and Adhesion in Waldenstrom’s Macroglobulinemia. (2006) (2)
Targeting mitochondria to overcome conventional and Bortezomib-resistance in multiple myeloma cells. (2003) (2)
Mechanisms, biologic sequelae and clinical benefits of bortezomib-induced immunogenic cell death in multiple myeloma (2019) (2)
Targeting Immune Suppressive Microenvironment By Immune Checkpoint Blockade in Multiple Myeloma (2014) (2)
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy (2000) (1)
Novel Combination Therapies for the Treatment of Relapsed/Refractory Multiple Myeloma: Current Phase I/II Combinations (2009) (1)
Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma (2022) (1)
The Small-Molecule VEGF-Receptor Inhibitor Pazopanib (GW786034B) Targets Both Tumor and Endothelial Cells in Multiple Myeloma. (2006) (1)
Clinical, Radiographic, and Biomarker Characterization of Multiple Myeloma Patients with Bisphosphonate Associated Osteonecrosis of the Jaw. (2006) (1)
Advances in Brief Functional Interaction between Retinoblastoma Protein and Stress-activated Protein Kinase in Multiple Myeloma Cells 1 (1999) (1)
Gene expression analysis of tumor cells sensitive and resistant to PS-341 (Bortezomib) treatment: Clinical implications. (2003) (1)
Nuclear Magnetic and Mechanical Relaxations in the γ-Loss Band of Linear Polyethylene Treated with Fuming Nitric Acid (1984) (1)
A Novel SIRT1 Activator SIRT1720 Triggers In Vitro and In Vivo Cytotoxicity In Multiple Myeloma Via ATM-Dependent Mechanism (2010) (1)
Inhibition Of H3K27-Methylome As a Novel Therapeutic Strategy In Multiple Myeloma (2013) (1)
Nuclear Magnetic and Mechanical Relaxations in the γ-Loss Band of Linear Polyethylene Irradiation with γ-Rays (1984) (1)
Niche-Based Screening Identifies Novel Small Molecules That Overcome Stromal Effects in Multiple Myeloma (2012) (1)
NVP-AEW541: A Selective Small Molecule IGF-1R Tyrosine Kinase Inhibitor Is Active Against Multiple Myeloma and Other Hematologic Neoplasias and Solid Tumors. (2004) (1)
[Proteasome inhibitor bortezomib as an anticancer drug]. (2006) (1)
Bcl6 as a Novel Therapeutic Target in Multiple Myeloma (MM). (2009) (1)
Significant Biological Role of Sp1 Transactivation in Myeloma: Potential Therapeutic Application. (2009) (1)
beta-Lapachone is safe and effective in Biege-Nude-Xid mouse xenograft model of human plasmacytoma. (2001) (1)
Interactions of the Mdm2/p53 and Proteasome Pathways: Implications for Combination Strategies to Enhance the Anti-Myeloma Activity of Bortezomib (2008) (1)
Critical role for Hck-mediated phosphorylation of Gab1 and Gab2 docking proteins in IL-6- induced proliferation and survival of MM cells (2004) (1)
Expression and Modulation of Carbohydrate-Binding Protein Galectin-3 in Multiple Myeloma Cells by Combined Treatment with GCS-100 and Dexamethasone. (2005) (1)
synergistic in myeloma cells hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are -tubulin α Aggresome induction by proteasome inhibitor bortezomib and (2013) (1)
The Role of the ABL1/YAP1/P73 Axis in Prevention of DNA Damage-Mediated Apoptosis in Multiple Myeloma (2012) (1)
Molecular Profiling of Extramedullary and Medullary Plasmacytomas. (2008) (1)
A349 Phase I/II Trial of Perifosine + Bortezomib in Rel/Ref MM Patients Previously Treated with Bortezomib (2009) (1)
The Oncogene MYC Triggers Replicative Stress and DNA Damage In Multiple Myeloma (2013) (1)
1 JSK , a GST-activated nitric oxide generator , induces DNA double strand breaks , activates DNA damage response pathways , and induces apoptosis in vitro and in vivo in human multiple myeloma cells (2007) (1)
In vitro and in vivo proteasome activity profiles of bortezomib and a novel proteasome inhibitor NPI-0052 (2005) (1)
CYC065, a Potent Derivative of Seliciclib Is Active In Multiple Myeloma In Preclinical Studies (2010) (1)
B037 CAL-101: A Selective Inhibitor of PI3K p110D for the Treatment of Multiple Myeloma (2009) (1)
The effect of selective inhibition of HDAC6 with ACY1215 on bortezomib activity in multiple myeloma (MM). (2011) (1)
Whole-genome bisulfite sequencing identifies HDAC3-mediated DNA methylation in multiple myeloma (2019) (1)
Inhibition of Histone Deacetylase 6 Effects on Interaction of Tumor and Immune Cells In Multiple Myeloma (2010) (1)
The Role of B Cell-Activating Factor (BAFF) in the Biology of Multiple Myeloma (MM). (2005) (1)
Atiprimod (N-N-diethl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) Inhibits Myeloma in Vivo. (2004) (1)
MLN 120 B , a Novel I K BKinase B Inhibitor , Blocks Multiple Myeloma Cell Growth In vitro and In vivo (2006) (1)
inhibition myeloma cells via mTORC 1 and extracellular signal-regulated kinase salvage pathway induces autophagy in multiple + Targeting NAD (2012) (1)
The BAFF Inhibitor AMG523 Blocks Adhesion and Survival of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment: Clinical Implication. (2006) (1)
Novel Therapeutic Rationale for Targeting HDAC1 and PIM2 in Multiple Myeloma (2019) (1)
Change of Distribution of Free Volume in a Polymer Caused by Crystallization (1999) (1)
Thalidomide analogue IMiD3 provides T cell co-stimulation through B7-CD28 pathway. (2002) (1)
DEPTOR Is a Regulator of Response to mTOR Kinase Inhibitors in Multiple Myeloma (2011) (1)
Targeting Cyclin D1 in the Treatment of Multiple Myeloma: Preclinical Validation of a Novel Specific Small Molecule Cyclin D1 Inhibitor, P276-00. (2006) (1)
Inhibition Of Myeloid Derived Suppressor Cells (MDSC) In The Multiple Myeloma Bone Marrow Microenvironment (2013) (1)
Nanoparticle Arsenic Compound Realgar Effectively Targets Myeloma Stem-Like Side Population (2013) (1)
Pembrolizumab (anti-PD-1) Treatment Increases Anti-Tumor Activities of XBP1/CD138/CS1-Specific Cytotoxic T Lymphocytes Against Multiple Myeloma (2017) (1)
Histone Deacetylase Inhibitors in Multiple Myeloma (2008) (1)
Abstract 2530: Antimyeloma activity of a small molecule multi-targeted kinase inhibitor, AT9283, via potent aurora kinase and STAT3 inhibition (2010) (1)
Endothelial Cells Induce Multiple Myeloma Cell Proliferation Protect Against Conventional and Novel Therapies. (2004) (1)
Serine/Threonine Kinase STK4 Is a Novel Target in Myeloma (2014) (1)
Myeloma Patient-Derived Mesenchymal Stem Cells Grown In 3-D Culture Induce Primary Myeloma Cell Proliferation and Resistance To Therapy (2013) (1)
Effect of the specific P53 stabilizer CBS9106 on multiple myeloma (MM). (2016) (1)
The monoclonal antibody nBT 062 conjugated to maytansinoids has potent and selective cytotoxicity against CD 138 positive multiple myeloma cells in vitro and in vivo (2008) (1)
Low Levels of Circulating CS1, a Newly Identified Multiple Myeloma (MM) Antigen for a Novel Humanized HuLuc63 Monoclonal Antibody, Is Detected in MM Patient Sera and Correlates with Active Disease. (2007) (1)
Serotonin Receptor Antagonists Have an In Vitro and In Vivo Anti-Myeloma Effect That Is Mainly Mediated by Caspase Dependent Apoptosis. (2006) (1)
JAK-STAT3 Pathway Regulates CD38 Expression on Multiple Myeloma Cells (2018) (1)
HDAC3 Maintains DNMT1 through Dual Mechanisms in Multiple Myeloma (2016) (1)
Lysine Demethylase 5A is Required for MYC Driven Transcription in Multiple Myeloma. (2021) (1)
Abstract B100: Development of fargeted multiple myeloma cancer vaccine and antigen-specific T-cell immunotherapy using novel Immunogenic-engineered heteroclitic BCMA peptides (2019) (1)
Phenotypic and Functional Effects of Novel Akt Inhibitor Perifosine on Immune System. (2008) (1)
Requirement of Caspase-8 Versus Caspase-9 during Apoptosis in Multiple Myeloma Cells Induced by Bortezomib- or a Novel Proteasome Inhibitor NPI-0052. (2005) (1)
Intracellular NAD + Depletion Enhances Bortezomib-Induced Myeloma Cytotoxicity (2012) (1)
PRMT5 inhibitors on the (myeloma) road (2018) (1)
The In Vivo Activity of Neutralizing B Cell-Activating Factor (BAFF) Antibody in the Treatment of Multiple Myeloma (MM). (2006) (1)
Anti-Tumor Activity of a Novel Immunosuppressant FTY720 in Multiple Myeloma. (2004) (1)
Analysis of Chemokine and Adhesion Markers in Waldenstrom Macroglobulinemia. (2006) (1)
Bortezomib Targets Multiple Myeloma Endothelial Cells. (2004) (1)
Myeloid Derived Suppressor Cells (MDSCs) Regulate Tumor Growth, Immune Response and Regulatory T Cell (Treg) Development in the Multiple Myeloma Bone Marrow Microenvironment (2012) (1)
In Vivo Anti-Tumor Activity of Atiprimod on SCID Models of Multiple Myeloma. (2005) (1)
The Change of Viscosity of Silicone Oils by γ-Irradiation (1958) (1)
R-Etodolac and a Novel Indole-Pyran Structural Analog, SDX-308, Induce Cytotoxicity and Overcome Drug Resistance in Multiple Myeloma. (2005) (1)
Reversine: A Chemical Probe Providing Insight into Myeloma Biology and Potential Therapeutic Applications. (2006) (1)
Non-steroidal anti-inflammatory drug therapy for chronic lymphocytic leukemia (2006) (1)
JS-K, a GST-Activated Nitric Oxide Generator, Induces Apoptosis and Overcomes In Vitro Drug Resistance in Multiple Myeloma Cells. (2005) (1)
Aberrant RHAMM Splicing in Multiple Myeloma (MM) and Its Implications for Immunotherapy (2019) (0)
The proteasome and proteasome inhibitors in multiple myeloma (2017) (0)
New Therapeutic Strategies in Multiple Myeloma (2012) (0)
High dose chemotherapy supported by autologous bone marrow transplantation to small cell lung cancer (1995) (0)
High dose of Zoledronic acid inhibits both osteoclasts and osteoblasts in an In Vivo mouse model (2008) (0)
Anti-Myeloma Activity of Two Novel N-Substituted and Tetraflourinated Thalidomide Analogues. (2004) (0)
B357 Targeting Myeloma Bone Disease via Activin A Inhibition (2009) (0)
Bone Marrow Niche Down-Regulates Mir-30 In Multiple Myeloma Cells to Promote Cancer Progression and Cancer Initiation by Targeting BCL9/Wnt Pathway. (2010) (0)
Immunomodulatory Effects of Histone Deacetylase 6 Inhibition in Suppressor Immune Cells in Multiple Myeloma (2011) (0)
OAB-009: Genome-wide CRISPR interference screen identifies RNA Regulator of Lipogenesis (RROL) as a leading LncRNA dependency in Multiple Myeloma (2021) (0)
In vivo activity of Atiprimod on SCID models of multiple myeloma (2005) (0)
Differential oxidative stress responses during 2-methoxyestradiol (2ME2) and dexamthasone (Dex)-induced apoptosis in multiple myeloma (MM) cells. (2002) (0)
Author Correction: Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma (2022) (0)
KDM5A reinforces MYC transcriptional program and promotes myeloma cell growth (2019) (0)
Abstract 5352: Genome-wide CRISPR-cas9 screening identifies KDM6A as a modulator of CD38 expression in multiple myeloma: Therapeutic implications (2022) (0)
Chapter 2 Resistance to Proteasome Inhibitors in Multiple Myeloma (2017) (0)
Myeloma Bone Marrow Stromal Cells Detection of Kaposi's Sarcoma Herpesvirus DNA Sequences in Multiple (2013) (0)
Role of ubiquitin-conjugating enzyme CDC34 in multiple myeloma. (2003) (0)
against apoptosis VEGF induces MCL-1 upregulation and protects multiple myeloma cells (2013) (0)
Preclinical Validation of a Clinical Grade Novel Specific Small Molecule Cyclin D1 Inhibitor, P276-00 for the Treatment of Multiple Myeloma. (2007) (0)
Molecular Motions and Related Mechanical Relaxations in Linear Polyethylene Treated with Fuming Nitric Acid (1986) (0)
[Effect of splenectomy in gastric carcinoma surgery on cell-mediated immunity; evaluation with alteration of peripheral blood lymphocyte subsets]. (1987) (0)
Where is the “Attention Deficit” in ADHD? Perspectives from Cognitive Neuroscience and Recommendations for Future Research (2007) (0)
The Novel, Orally Available Multi-Kinase Inhibitor BAY 73-4506 in Multiple Myeloma (2008) (0)
Rectal carcinoma: Is it able to expect stage and prognosis by colonoscope? (1998) (0)
Identification a Novel Molecular Mechanism Underlying the Anti-CD38-Based Treatment Resistance in Multiple Myeloma Patients (2022) (0)
The influence of pyrimidine nucleoside phosphorylase activity on metastasis of breast cancer. (1997) (0)
Effect of Presence of Diluent on Molecular Motion of Polyethylene Single Crystals with and without Surface-Crosslinks (1976) (0)
Novel Mechanisms Underlying IMiDs Resistance in Multiple Myeloma: Therapeutic Implications (2017) (0)
Myeloma Resistance and is Well Tolerated in Patients with Relapse Multiple Immunomodulatory Derivative of Thalidomide CC-5013 Overcomes Drug (2013) (0)
Effect of the Pan-PIM Kinase Inhibitor, AZD1208, Alone and in Combination with Bortezomib in Multiple Myeloma (2014) (0)
Targeting Ribonucleotide Reductase M1 and M2 in Multiple Myeloma (2016) (0)
Hsp90 Is Critical for the Regulation of Phenotype and Functionality of Human Dendritic Cells. (2005) (0)
Enhanced CD138 peptide-specific cytotoxic T lymphocyte activities against breast, colon and pancreatic cancers in combination with pembrolizumab (anti-PD1). (2019) (0)
Cancer Therapy: Preclinical A High-Affinity Fully Human Anti–IL-6 mAb, 1339, for the Treatment of Multiple Myeloma (2009) (0)
Role of BAFF in Adhesion and Growth of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment. (2005) (0)
Molecular Characterization of PS-341 (bortezomib) Resistance: Implications for Overcoming Resistance Using Lysophosphatidic Acid Acyltransferase (LPAAT)-β Inhibitors. (2004) (0)
Super-Enhancer-Driven PIM Kinase Upregulation in Multiple Myeloma Maintains the Plasma Cell-Specific Oncogenic and Microenvironmental Circuits, and Can be Efficiently Targeted By the Pan-PIM Inhibitor MEN1703 (2022) (0)
CCL3 Impairs Osteoblast Function Via Downregulation of Osteocalcin. (2009) (0)
Identification of Novel Targets Based on Splicing Alterations for Undruggable RAS/CDK Signaling Cascade in Multiple Myeloma (2021) (0)
Dysfunctions of innate and adaptive immune tumor microenvironment in Waldenström macroglobulinemia (2022) (0)
The induction of cytotoxicity by a bispecific antibody against CEA positive cell line, in vitro (1996) (0)
Abstract B09: Exploiting oncogene-induced DNA replicative stress as synthetic lethal approach to target myeloma. (2015) (0)
Splenic autotransplantation following total gastrectomy with splenectomy for gastric carcinoma. (1985) (0)
Compositions for treating cancer using the proteasome inhibitor PS-341 (2003) (0)
Abstract 2004: Phenotypic and molecular characterization of inter- and intraclonal heterogeneity in multiple myeloma and Waldenstrom macroglobulinemia (2015) (0)
Scientific section designations: Lymphoid Neoplasia Title: p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma Short title: TP53RK is a novel therapeutic target in myeloma (2016) (0)
IMW Section B (2009) (0)
TNF-α Confers Resistance of Myeloma Cells to IMiDs through TRAF2 Degradation (2019) (0)
BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma (2023) (0)
Lack of Mcl-1 Confers Resistance to Bortezomid in Multiple Myeloma. (2004) (0)
Enhanced cytotoxicity of monoclonal antibody SGN-40 and immunomodulatory drug IMiD3 against human multiple myeloma (2004) (0)
Development of PRPK Directed Phthalimides (2021) (0)
Halofuginone, an Old Anticoccidosis Drug, Induces Apoptosisin Multiple Myeloma Cells, Associated with Down Regulation of MCL1. (2007) (0)
Dual Inhibition of Canonical and Non-Canonical NF-KB Pathway Demonstrates Significant Anti-Tumor Activities in Multiple Myeloma (MM) (2011) (0)
macroglobulinemia The Akt pathway regulates survival and homing in Waldenstrom (2008) (0)
Long Noncoding RNA RROL Provides Chromatin Scaffold for MYC-WDR82 Interaction to Impact Lipid Metabolism and Tumor Cell Growth in Multiple Myeloma (2021) (0)
Molecular Profiling of Extramedullary and Medullary Plasmacytomas Compared to Multiple Myeloma (2010) (0)
B in Waldenstrom macroglobulinemia κ Targeting NF (2013) (0)
Targeting Replicative Stress to Treat Hematological Disorders (2015) (0)
Isothermal Thinning of Crystal Lamella of Polyethylene Observed by NMR Measurement (1975) (0)
Author Correction: The biological significance of histone modifiers in multiple myeloma: clinical applications (2021) (0)
Treatment of solid tumors (2006) (0)
B457 AT7519, a Multi-Cyclin Dependent Kinase Inhibitor, Induces Apoptosis in Multiple Myeloma via GSK3B (2009) (0)
Mcl-1 Fragment Mcl-1(128–350) Induces Inhibition of Multiple Myeloma Cell Proliferation and Apoptosis Via Both Upregulation of C-Jun as Well as Modulation of Its Transcriptional Activity (2008) (0)
synergistic activity in multiple myeloma Combination of the mTOR inhibitor rapamycin and CC-5013 has (2013) (0)
Correction: Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma (2019) (0)
Rational for a Combination of Bortezomib and Doxorubicin in the Treatment of Multiple Myeloma: A Pivotal Role for Mcl-1. (2007) (0)
P-085: Resistance to immunogenic cell death as a novel mechanism of immune escape in high-risk multiple myeloma (2022) (0)
In vitro and in vivo antitumor activity of the maytansinoid immunoconjugate BB-10901 (huN901-DM1) on CD56+multiple myeloma cells. (2003) (0)
Development TACI and Bcma Dual-Antigen Targeted Immunotherapy for Multiple Myeloma (2019) (0)
Is invasion of lymphatic vessei diagnosed before operation in gastric carcinoma (1998) (0)
Table 136-3, Classification of Monoclonal Gammopathies (2003) (0)
malignant B cells Molecular sequelae of histone deacetylase inhibition in human (2013) (0)
Bioprocessing of MIR17HG Results in Long and Short Noncoding RNAs with Targetable Tumor-Promoting Activity in Multiple Myeloma (2022) (0)
Biology and Therapeutic Targeting of Sp1 Transactivation In Myeloma (2010) (0)
BIRB796 Inhibits p38 MAPK/Hsp27 Pathway and Enhances Cytotoxicity Triggered by Bortezomib, Hsp90 Inhibitor, and Dexamethasone in Multiple Myeloma. (2006) (0)
In Vitro Activity of a Novel Small Molecule Cyclin Dependent Kinase Inhibitor, CYC202 (seliciclib or R-Roscovitine), in Multiple Myeloma (MM). (2004) (0)
The Novel, Orally Available Multi-Kinase Inhibitor BAY 73-4506 Targets Myeloma Cells and Their Bone Marrow Microenvironment. (2007) (0)
B469 Unraveling the Synergism of Nab-Rapamycin and Perifosine Combination in Multiple Myeloma (2009) (0)
Sp1 Transcription Factor as a Novel Therapeutic Target in Multiple Myeloma (MM) (2008) (0)
Up-Regulation of c-Jun contributes to the Induction of Apoptosis by Adaphostin in Human Multiple Myeloma Cells. (2005) (0)
Clinical statistics of gastric cancer in the second department of surgery, school of medicine, Fukuoka University over the last decade (1995-2004) (2007) (0)
Clinical implications for optimizing the approach to topoisomerase 1 as a therapeutic target in multiple myeloma (MM). (2003) (0)
microenvironment migration of multiple myeloma cells in the bone marrow GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and (2013) (0)
A novel non-peptide and orally active proteasome inhibitor overcomes bortezomib-resistance in multiple myeloma (MM) cells (2005) (0)
JNK activation and Fas up-regulation precede proteasomal degradation of topoisomerase I in SN38-mediated cytotoxicity against multiple myeloma. (2004) (0)
Upregulation of c-Jun Induces Cell Death Via Caspase-Triggered c-Abl Cleavage in Human Multiple Myeloma. (2006) (0)
Cytokines in Multiple Myeloma (2007) (0)
Selective Targeting of Multiple Myeloma By Bcma-Specific Central Memory CD8+ cytotoxic T Lymphocytes: A Potential Immunotherapeutic Application in Multiple Myeloma and Other Plasma Cell Disorders (2018) (0)
OAB-033: Loss-of-function of GABARAP drives tumor resistance to bortezomib-induced immunogenic cell death in multiple myeloma (2021) (0)
Biological pathways and in vivo anti-tumor activity induced by atiprimod in multiple myeloma (MM). (2006) (0)
CCL5 (RANTES) Is Suspected to Be the Key Chemokine to Understand the Bone Pathology of Multiple Myeloma (2008) (0)
RNA Regulator of Lipogenesis (RROL) Is a Novel Lncrna Mediating Protein-Protein Interaction at Gene Regulatory Loci Driving Lipogenic Programs in Multiple Myeloma (2020) (0)
Evaluation of Immune Profile in Patients with Multiple Myeloma Using Cytof Technology (2014) (0)
Nonspecific cross-reacting antigen 5090 is elevated in patients with gastric cancer (1995) (0)
well tolerated in patients with relapsed multiple myeloma Immunomodulatory drug CC-5013 overcomes drug resistance and is (2013) (0)
Purification and analysis of immunosuppressive substance derived from malignant pleural effusion of lung cancer patients (1996) (0)
Upregulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma and other malignancies (2007) (0)
Targeting therapy for resistant multiple myeloma with a novel inhibitor of NF-KB, NPI-1387. (2005) (0)
Heterogeneity of B cell lymphopoiesis in patients with premalignant and active myeloma (2023) (0)
B026 CS1 Promotes Multiple Myeloma Cell Adhesion, Clonogenic Growth, and Tumorigenicity via c-Maf Mediation (2009) (0)
synergistic cytotoxicity in multiple myeloma vivo in Combination of proteasome inhibitors bortezomib and NPI-0052 trigger (2012) (0)
Targeting myeloma metabolisms regulated by HDAC1-IRF4 axis can be a novel therapeutic strategy (2019) (0)
The role of membrane raft in modulating CD40 signaling, ERK activation and cytokine production in human multiple myeloma cells. (2003) (0)
Aberrant RHAMM (receptor for hyaluronan-mediated motility) splicing in MM is associated with upregulation of PTBP1/2 (polypyrimidine tract binding protein 1/2): therapeutic implications (2019) (0)
Targeting Proteinkinase C Alters ER-Stress and b-Catenin Signaling in Multiple Myeloma: Therapeutic Implications. (2007) (0)
Myeloma Microenvironment Controls T Regulatory Cell Activity: Potential Target for Therapeutic Interventions. (2006) (0)
Mimicking Myeloma Niche Ex Vivo (2014) (0)
Role Of Sirtuin-6 In Maintenance Of Genomic Instability In Multiple Myeloma Cells (2013) (0)
Arginine Methylation Mediated By PRMT5 Has Significant Biological and Clinical Impact in Multiple Myeloma (2016) (0)
Altered Genomic and Epigenetic Profiling of Myeloma Bone Marrow Stromal Cells Identifies Targets for Current and Future Immunotherapeutic Approaches (2019) (0)
Biologic impact of proteasome inhibition in MM cells - from the aspects of preclinical studies (2012) (0)
Akt Inhibitor Perifosine-Induced Cytotoxicity Is Associated with Significant Downregulation of Survivin in Human Multiple Myeloma (MM) Cells. (2006) (0)
Thalidomide in multiple myeloma in the elderly (2009) (0)
Pomalidomide for the treatment of relapsed and refractory multiple myeloma (2014) (0)
P-089: Identification of novel targets in multiple myeloma for “undruggable” RAS/CDK signaling cascade (2021) (0)
Targeting the Ubiquitin-proteasome System in Multiple Myeloma: Examining the Roots of Success (2015) (0)
Identification of Novel Antigens with Induced Immune Response in MGUS. (2006) (0)
Genome-Wide CRISPR-Cas9 Screen Identifies KDM6A As a Modulator of Daratumumab Sensitivity in Multiple Myeloma (2022) (0)
Delineation of Canonical and Non-Canonical NF-κB Pathways in Multiple Myeloma: Therapeutic Implications. (2007) (0)
MLN3897, a Novel CCR1 Antagonist, Inhibits Osteoclastogenesis by Blocking Early ERK Activation. (2006) (0)
Rational Combination Treatment of a Novel Selective mTOR Kinase Inhibitor AZD8055 with IGF-1R Inhibitors in Multiple Myeloma (2012) (0)
Bcl-2, Mcl-1 and p53 Expression Confer Sensitivity to Bcl-2 Inhibitor ABT-737 in Multiple Myeloma. (2006) (0)
ANALYSIS OF COLORECTAL CANCERS WITH LIVER METASTASIS (1991) (0)
relapsed, refractory multiple myeloma Clinical factors predictive of outcome with bortezomib in patients with (2013) (0)
Preclinical Activities of Bortezomib in MM, the Bone Marrow Microenvironment and Pharmacogenomics (2011) (0)
Bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic apoptosis in multiple myeloma (MM) cells (2003) (0)
(LY317615.HCl) novel, orally available small-molecule inhibitor enzastaurin Targeting PKC in multiple myeloma: in vitro and in vivo effects of the (2013) (0)
Traitement de troubles lies a la degradation de proteines (2006) (0)
myeloma interaction of tumor and bone marrow accessory cells in multiple Immunomodulatory effects of lenalidomide and pomalidomide on (2012) (0)
A Novel Acanthoic Acid Analog NPI-1342 Blocks IκB Kinase-α and Trigger In Vitro and In Vivo cytotoxicity in Multiple Myeloma Cells (2011) (0)
Immunohistologic study on an autotransplanted spleen in man - A case report. (1986) (0)
B569 Targeting the Sp1 Transcription Factor in Multiple Myeloma (2009) (0)
Proteasome inhibitors: beyond NFKB inhibition alone and the emerging role of combination therapy in the treatment of multiple myeloma (2009) (0)
Identification Of Novel Alternative Splice Variants Of Sirtuins In Multiple Myeloma: Therapeutic Implications (2013) (0)
Sulforaphane and PEITC Augment Activity of Conventional and Novel Anti-Myeloma Drugs (2008) (0)
Epigenetic Modulation by Vidaza™ induces Apoptosis and Overcomes In Vitro Drug Resistance in Human Multiple Myeloma Cells. (2006) (0)
Phenotypic and Functional Effects of Novel HDAC Inhibitor LBH589 On Human Lymphocyte Populations. (2009) (0)
Nuclear Magnetic Resonance Study of Molecular Motions in Poly(γ-n-alkyl L-glutamate)s (1986) (0)
The Biological Sequelae of Stromal Cell-derived Factor-1 (cid:1) in Multiple Myeloma 1 (2002) (0)
Perifosine Affects Phenotype and Function of Human Myeloid Dendritic Cells (2010) (0)
cells in the multiple myeloma microenvironment in humans Tumor-promoting immune-suppressive myeloid-derived suppressor (2013) (0)
A Novel Real-Time In Vivo Homing Model of Multiple Myeloma. (2006) (0)
The JAK inhibitor INCB20 induces antiproliferative and apoptotic effects in human myeloma cells in vitro and in vivo (2005) (0)
A RESECTED CASE OF ADVANCED ESOPHAGEAL CARCINOMA SHOWING A PROMINENT RESPONSE TO NEOADJUVANT CHEMOTHERAPY WITH 5-FU AND LEUCOVORIN (1995) (0)
An Investigational Novel Orally Bioavailable Proteasome Inhibitor MLN9708/MLN2238 Triggers Cytotoxicity In Multiple Myeloma Cells Via p21- and Caspase-8-Dependent Signaling Pathway (2010) (0)
Novel Etodolac Analog SDX-308 (CEP-18082) Induces Cytotoxicity in Multiple Myeloma Cells Associated with Inhibition of Wnt/β-Catenin Pathway. (2006) (0)
Change of Distribution of Free Volume in a Polymer Caused by Cross-Linking (2002) (0)
Phenotypic and Functional Effects of Perifosine on Dendritic Cells. (2007) (0)
Caveolin-1 Is Required for VEGF- Triggered Multiple Myeloma Cell Migration and Is Targeted by Bortezomib (Velcade®). (2004) (0)
therapeutic applications B blockade in multiple myeloma: κ - Biologic sequelae of nuclear factor (2013) (0)
Clonal Heterogeneity and Immune Tumor Microenvironment in Waldenström Macroglobulinemia (2019) (0)
Identification of disease-related aberrantly spliced transcripts in myeloma and strategies to target these alterations by RNA-based therapeutics (2023) (0)
Abstract PR04: Exploiting oncogene-induced DNA replicative stress as synthetic lethal approach to target myeloma. (2015) (0)
Anti-Tumor Activities of XBP1 Antigen-Specific Cytotoxic T Lymphocytes Are Enhanced By HDAC6 Inhibitor ACY241 (2016) (0)
Optimizing Mechanisms for Induction of Immunogenic Cell Death to Improve Patient Outcome in Multiple Myeloma (2018) (0)
stromal cells mediated interactions with bone marrow - tumorigenicity via c-maf CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and (2013) (0)
High-dimensional Clonal Heterogeneity and Immune Landscape in Multiple Myeloma (2019) (0)
Corrigendum to <'Novel therapeutic strategies for multiple myeloma'> <[Experimental Hematology 2015; 43: 732-741]>. (2021) (0)
A Novel Inosine Monophosphate Dehydrogenase Inhibitor VX-944 Overcomes Conventional Drug-Resistance in Multiple Mueloma Cells in the Bone Marrow Microenvironment. (2004) (0)
Overcoming p53 Loss with a Multi-Targeted Small Molecule Inhibitor in Multiple Myeloma. (2009) (0)
Pull-through esophagectomy without thoracotomy in the surgical treatment for carcinoma of the thoracic esophagus. (1985) (0)
Targeting CCR1 for the Treatment of Osteolytic Bone Disease in Multiple Myeloma. (2007) (0)
patients with newly diagnosed multiple myeloma Lenalidomide, bortezomib, and dexamethasone combination therapy in (2012) (0)
MLN120B, a Novel IKBKinase B Inhibitor, Blocks Multiple Myeloma Cell Growth In vitro and In vivo (2006) (0)
Novel antimyeloma therapeutic option with inhibition of the HDAC1-IRF4 axis and PIM kinase (2022) (0)
Alkylphosphocholine Perifosine Inhibits Myeloma Cell Growth While Inducing Myeloid Hyperplasia in a Murine Myeloma Model. (2005) (0)
The Role of Heat Shock Protein 90 as a Therapeutic Target for Multiple Myeloma (2008) (0)
The novel, orally available small- molecule PKC inhibitor enzastaurin (LY317615.HCl) in multiple myeloma: in vitro and in vivo effects and therapeutic implications (2007) (0)
Inter and Intra-Clonal Heterogeneity in Multiple Myeloma and Waldenstrom Macroglobulinemia (2014) (0)
The Role of Bortezomib in the Treatment of Relapsed and Refractory Multiple Myeloma (2008) (0)
CCR1 Inhibition Targets Osteoclast-Myeloma Adhesion and Exerts in Vivo Anti-Osteoclast Activity (2008) (0)
Correction: HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer (2021) (0)
VEGF Upregulates Mcl-1 Expression and Protects Multiple Myeloma Cells Against Starvation Induced-Apoptosis. (2004) (0)
Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma (2023) (0)
B540 The Effect of Insulin-Like Growth Factor-1 in Waldenström Macroglobulinemia (2009) (0)
inhibiting STAT3 Nifuroxazide inhibits survival of multiple myeloma cells by directly (2013) (0)
Cancer Therapy : Preclinical Dual Inhibition of Canonical and Noncanonical NFk B Pathways Demonstrates Signi fi cant Antitumor Activities in Multiple Myeloma (2012) (0)
Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma (2023) (0)
Other Plasma Cell Dyscrasias (2003) (0)
Discovery of Prolyl-tRNA Synthetase As a Novel Target in Multiple Myeloma (2021) (0)
Antitumor Activities Of An Oral Selective HSP90α/β Inhibitor, TAS-116, In Combination With Bortezomib In Multiple Myeloma (2013) (0)
Molecular Motions and Mechanical Relaxations of Poly(Carbonate) in the Glassy State (1989) (0)
ROLE OF NITRIC OXIDE IN MODULATING MUCOSAL PERMEABILITY AND MITIGATING BACTERIAL TRANSLOCATION FROM THE RAT COLON (1997) (0)
Epigenetic modulation by VidazaTM induces apoptosis and overcomes in vitro drug resistance in human multiple myeloma cells. (2007) (0)
in vivo synergistic cytotoxicity in multiple myeloma Combination of proteasome inhibitors bortezomib and NPI-0052 trigger (2008) (0)
CCR1 Inhibition Impairs Osteoclast Activity and Interaction with Myeloma Cells. (2006) (0)
Immmunomodulatory Drug (Revamid) Co-stimulates T cells via The B7-CD28 pathway (2003) (0)
Erratum (2006) (0)
Niches Within the Multiple Myeloma Bone Marrow Microenvironment (2007) (0)
Abstract 642: TRAF2 mediates sensitivity to immunomodulatory drugs via NF-κB and ERK signaling in myeloma cells (2020) (0)
Expression ofHRF20,a regulatory molecule ofcomplementactivation, on peripheral bloodmononuclear cells (1990) (0)
High-Dimensional Heterogeneity of Waldenström Macroglobulinemia within Its Immune Tumor Microenvironment (2019) (0)
Abstract LB193: Lysine demethylase 5A is required for MYC driven transcription in multiple myeloma (2021) (0)
Hsp90 Is Critical for the Regulation of Human T Lymphocytes and NK Cell Phenotype and Function. (2005) (0)
Dendritic cells efficiently internalize and process exogenous peptides despite proteasome inhibition. (2002) (0)
LYMPHOID NEOPLASIA MUC1-C drives MYC in multiple myeloma (2016) (0)
A CASE OF EARLY GASTRIC CANCER OCCURING IN THE MUCOSA ON AN ABERRANT PANCREAS OF THE STOMACH (1995) (0)
Monoclonal Antibody–Based Therapies in Human Multiple Myeloma (2009) (0)
proteasome inhibitor PS-341 resistance in multiple Targeting mitochondria to overcome conventional and (2004) (0)
Activation of B-Cell Maturation Antigen (BCMA) on Human Multiple Myeloma Cells by a Proliferation-Inducing Ligand (APRIL) Promotes Myeloma Cell Function in the Bone Marrow Microenvironment. (2007) (0)
Inhibition of Hsp90 Targets Multiple Myeloma Cell Growth, Angiogenesis, and Osteoclastogenesis in the BM Microenvironment. (2007) (0)
Loss-of-Function of Gabarap Impairs Bortezomib-Induced Anti-Tumor Immunity in Multiple Myeloma: Clinical Application (2019) (0)
ß-Catenin Is a Novel Marker of the Aggresome and Suggests Disruption of the Proteasome-Aggresome-Autophagasome Pathway in Multiple Myeloma In Vivo. (2006) (0)
Small Molecule Therapeutics Delineating themTORKinasePathwayUsingaDual TORC 1 / 2 Inhibitor , AZD 8055 , in Multiple Myeloma (2014) (0)
B454 Mcl-1 Fragment Mcl-1128-350 Induces Inhibition of Multiple Myeloma Cell Proliferation and Apoptosis (2009) (0)
Histone Deacetylase-6 (HDAC6) Modulates Akt and STAT3 Activity Via Heat Shock Protein (Hsp) 90 in Human Multiple Myeloma (MM) Cells. (2006) (0)
Myeloma Heterogeneity within Its Complex Immune Ecosystem (2019) (0)
A CASE REPORT OF BOCHDALEK HERNIA ASSOCIATED WITH GASTRIC VOLVULUS IN AN ADULT (1984) (0)
Procedes et compositions de traitement du cancer au moyen d'inhibiteurs de la proteasome (2003) (0)
A new model of plasma cell proliferation (2004) (0)
Induction of Apoptosis by Didox Via Down-Regulation of Bcl-2 Family Proteins in Multiple Myeloma (MM). (2004) (0)
In Vivo Effects of Zoledronic Acid on Bone Remodeling. (2007) (0)
BRD9 Is Essential for Ribosome Biogenesis and the Survival of Multiple Myeloma Cells (2022) (0)
Multiple Myeloma Cell-Osteoblast Interaction Results in Impaired Bone Formation. (2007) (0)
Targeting Autophagy to Overcome Resistance to Immunogenic Chemotherapy in High-Risk Multiple Myeloma (2022) (0)
Dietary Supplement Vitamin C Significantly Abrogates Bortezomib-Induced Multiple Myeloma (MM) Cell Growth Inhibition (2008) (0)
Author Correction: The biological significance of histone modifiers in multiple myeloma: clinical applications (2018) (0)
marrow milieu Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone (2013) (0)
Increased TCF-4 Expression Correlates with Reduced Caspase-3 Induction and Confers Resistance to Bortezomib. (2004) (0)
The Role of the Bone Marrow Microenvironment in the Pathogenesis of Multiple Myeloma (2007) (0)
IL-17A-Mediated Notch Signaling in Multiple Myeloma (2014) (0)
beta-lapachone, a novel topoisomerase I inhibitor, has significant cytotoxicity against multiple myeloma (MM) cell lines and patient cells. (2001) (0)
Molecular Sequaele of Activin A-Dependent Osteoblast Inhibition in Myeloma. (2009) (0)
Bone Marrow Microenvironment Regulates Alternative Splicing Events in Myeloma Cells through Downregulation of RNA Binding Protein Fox2 (2014) (0)
B341 BAY 73-4506, A Novel Orally Available Multikinase Inhibitor in MM (2009) (0)
specific cytotoxic T lymphocytes - Ex vivo induction of multiple myeloma (2013) (0)
Inhibition of fatty acid synthase induces anti-tumor effect in multiple myeloma (2008) (0)
apoptosis myeloma by induction of caspase-dependent and -independent Honokiol overcomes conventional drug resistance in human multiple (2010) (0)
Identification and Validation of HLA-A24 XBP1us, XBP1sp, CD138, and CS1 Peptides to Generate Antigens Specific-Cytotoxic T Lymphocytes: Preclinical Basis for Vaccine Therapy in HLA-A24 Patients with Multiple Myeloma and Other Cancers (2016) (0)
TRAF2 Mediates Sensitivity to Immunomodulatory Drugs in the Bone Marrow Microenvironment (2020) (0)
antitumor activity in Waldenström macroglobulinemia Protein kinase C inhibitor enzastaurin induces in vitro and in vivo (2008) (0)
A model for the in vitro and in vivo growth of multiple myeloma in the bone marrow microenvironment. (2001) (0)
Targeting Src-family kinase activation and downstream molecular events to overcome MM cell growth, survival, and drug-resistance. (2005) (0)
[4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth In vitro and in vivo activity of atiprimod (N-N-diethl-8,8-dipropyl-2-azaspiro (2005) (0)
Modulation of Signaling Cascades by Inhibitors of Histone Deacetylase and Akt (2009) (0)
Inhibition of human plasmacytoma cell growth by a novel JAK kinase inhibitor. (2004) (0)
Targeting IKK Inhibits Multiple Myeloma (MM) Cell Growth in the Bone Marrow Microenvironment. (2004) (0)
Defining a Murine Model To Study Bone Disease in Multiple Myeloma (MM). (2006) (0)
SDX-101 Is Cytotoxic and Overcomes Drug Resistance in Multiple Myeloma. (2004) (0)
CYC202 (seliciclib or R-Roscovitine), a small molecule cyclin dependent kinase inhibitor, overcomes drug resistance via down-regulation of Mcl-1 in multiple myeloma (MM) (2005) (0)
The unusual presentation of mucinous carcinoma in the colon making preoperative diagnosis difficult: Report of a case (2004) (0)
Cell Type-Specific Deregulation of Polypyrimidine Tract- Binding Proteins (PTBPs) Drive Aberrant Splicing in Multiple Myeloma (MM) and Acute Myeloid Leukemia (AML) (2018) (0)
A227 Lenalidomide, Bortezomib, and Dexamethasone Is Active in High-Risk Relapsed/Refractory Myeloma (2009) (0)
Immunomodulatory Effects of Lenalidomide and Bortezomib on Bone Marrow Stroma Cell and CD4 T Cell Interaction in Multiple Myeloma. (2008) (0)
1 Targeting NF-κ B in Waldenstrom Macroglobulinemia (2008) (0)
p38MAPK Inhibitor LSN2322600 Modulates the Bone Marrow Microenvironment and Inhibits Osteoclastogenesis in Multiple Myeloma. (2006) (0)
Halofuginone, a Novel Antimyeloma Agent, Upregulates C-Jun, JNK and P-53 Protein in Vitro, and Inhibits Tumor Growth and Improves Survival in in Vivo Multiple Myeloma(MM) Animal Models (2008) (0)
Antitumor activity of the maytansinoid immunoconjugate B-B4 (B-B4-DM1) against CD138+multiple myeloma cells. (2003) (0)
A chimeric humanized anti-CD40 antibody renders human multiple myeloma (MM) cells refractory to the mitogenic and protective effects of IL-6 (2003) (0)
against CD138+ multiple myeloma cells DM1 - Cytotoxic activity of the maytansinoid immunoconjugate B-B4 (2013) (0)
RFP2 Modulates 20S Proteasome Activity, NF Kappa B Activation, and Tumor Cell Growth in Multiple Myeloma. (2009) (0)
Didox Induced Apoptosis Occurs by Inhibiting DNA Synthesis and Repair Via Down-Regulation of Ribonucleotide Reductase M1 in Multiple Myeloma (MM). (2005) (0)
Biologic Sequelae of CDC2 Inhibition in MM. (2007) (0)
From cell biology to therapy: lenalidomide in relapsed/refractory multiple myeloma (2009) (0)
Targeting the Protein Degradation Pathway in Multiple Myeloma with Synergistic, Selective Small Molecules. (2005) (0)
Pathway-Catenin / BCL 9 β Therapeutic Tool by Targeting the Oncogenic Wnt / miR-30-5 p Functions as a Tumor Suppressor and Novel (2014) (0)
The Tyrosine Kinase Inhibitor Adaphostin (NSC 680410), but Not Imatinib Mesylate, Inhibits Survival and Src Tyrosine Kinase Family- Triggered Signaling Pathways of MM Cells. (2004) (0)
migration and homing in multiple myeloma dependent - Mechanisms of regulation of CXCR4/SDF-1 (CXCL12) (2013) (0)
The occurrence of decay accelerating factor(DAF) on peripheral blood mononuclear cells in rheumatoid arthritis. With special reference to a possible etiologic relationship.:—with Special Reference to a Possible Etiologic Relationship— (1990) (0)
Synthetic Lethal Approaches to Exploit Replicative Stress in Aggressive Myeloma (2014) (0)
Formation of the Functional Niche in Vitro by Mimicking the Pathophysiological Features of the Bone Marrow Microenvironment in Multiple Myeloma (2012) (0)
Proteasome inhibition regulates survival and homing in Waldenstrom Macroglobulinemia (WM) (2008) (0)
B281 Ciliary Proteins and Hedgehog Pathway in Multiple Myeloma (2009) (0)
Abstract PR13: p53-related protein kinase is a novel prognostic marker and therapeutic target in multiple myeloma (2017) (0)
Compromised Nuclear Sirtuins Activity Sensitizes BRCA-Proficient multiple Myeloma Cells to DNA Damage Agents (2012) (0)
Molecular Mechanisms Regulating Resistance to the Akt Inhibitor Perifosine in Waldenstrom’s Macroglobulinemia, the Role of the ERK and PKC Pathways. (2006) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Teruo Hideshima?

Teruo Hideshima is affiliated with the following schools: